These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 26846820

  • 1. Effective Concentration of a Multikinase Inhibitor within Bone Marrow Correlates with In Vitro Cell Killing in Therapy-Resistant Chronic Myeloid Leukemia.
    Mu C, Wu X, Ma H, Tao W, Zhang G, Xia X, Shen J, Mai J, Sun T, Sun X, Arlinghaus RB, Shen H.
    Mol Cancer Ther; 2016 May; 15(5):899-910. PubMed ID: 26846820
    [Abstract] [Full Text] [Related]

  • 2. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Yun SM, Jung KH, Kim SJ, Fang Z, Son MK, Yan HH, Lee H, Kim J, Shin S, Hong S, Hong SS.
    Cancer Lett; 2014 Jun 28; 348(1-2):50-60. PubMed ID: 24657654
    [Abstract] [Full Text] [Related]

  • 3. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
    Lu T, Cao J, Zou F, Li X, Wang A, Wang W, Liang H, Liu Q, Hu C, Chen C, Hu Z, Wang W, Li L, Ge J, Shen Y, Ren T, Liu J, Xia R, Liu Q.
    Eur J Pharmacol; 2021 Apr 15; 897():173944. PubMed ID: 33581133
    [Abstract] [Full Text] [Related]

  • 4. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Gupta P, Kathawala RJ, Wei L, Wang F, Wang X, Druker BJ, Fu LW, Chen ZS.
    Cancer Lett; 2016 Dec 28; 383(2):220-229. PubMed ID: 27720778
    [Abstract] [Full Text] [Related]

  • 5. Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia.
    Gupta P, Zhang GN, Barbuti AM, Zhang X, Karadkhelkar N, Zhou J, Ding K, Pan J, Yoganathan S, Yang DH, Chen ZS.
    Cancer Lett; 2020 Mar 01; 472():132-141. PubMed ID: 31837444
    [Abstract] [Full Text] [Related]

  • 6. Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.
    Jin B, Wang C, Shen Y, Pan J.
    Cell Death Dis; 2018 Jan 22; 9(2):68. PubMed ID: 29358661
    [Abstract] [Full Text] [Related]

  • 7. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.
    Clin Cancer Res; 2009 Mar 01; 15(5):1686-97. PubMed ID: 19240172
    [Abstract] [Full Text] [Related]

  • 8. Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML).
    Wu J, Wang A, Li X, Chen C, Qi Z, Hu C, Wang W, Wu H, Huang T, Zhao M, Wang W, Hu Z, Liu Q, Wang B, Wang L, Li L, Ge J, Ren T, Xia R, Liu J, Liu Q.
    Cancer Biol Ther; 2019 Mar 01; 20(6):877-885. PubMed ID: 30894066
    [Abstract] [Full Text] [Related]

  • 9. Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.
    Chen M, Gallipoli P, DeGeer D, Sloma I, Forrest DL, Chan M, Lai D, Jorgensen H, Ringrose A, Wang HM, Lambie K, Nakamoto H, Saw KM, Turhan A, Arlinghaus R, Paul J, Stobo J, Barnett MJ, Eaves A, Eaves CJ, Holyoake TL, Jiang X.
    J Natl Cancer Inst; 2013 Mar 20; 105(6):405-23. PubMed ID: 23446755
    [Abstract] [Full Text] [Related]

  • 10. SHC004-221A1, a novel tyrosine kinase, potently inhibits T315I mutant BCR-ABL in chronic myeloid leukemia.
    Wang D, Zheng Y, Li J, Wu H, Li X, Tang Y, Liu Y, Li J, Sun R, Zhou Y, Sun J, Yang Y.
    Eur J Pharmacol; 2017 Sep 15; 811():117-124. PubMed ID: 28595903
    [Abstract] [Full Text] [Related]

  • 11. PBA2, a novel inhibitor of the β-catenin/CBP pathway, eradicates chronic myeloid leukemia including BCR-ABL T315I mutation.
    Yang K, Fu K, Zhang H, Wang X, To KKW, Yang C, Wang F, Chen ZS, Fu L.
    Mol Cancer; 2024 Sep 28; 23(1):209. PubMed ID: 39342174
    [Abstract] [Full Text] [Related]

  • 12. CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia.
    Guerra B, Martín-Rodríguez P, Díaz-Chico JC, McNaughton-Smith G, Jiménez-Alonso S, Hueso-Falcón I, Montero JC, Blanco R, León J, Rodríguez-González G, Estévez-Braun A, Pandiella A, Díaz-Chico BN, Fernández-Pérez L.
    Oncotarget; 2017 May 02; 8(18):29679-29698. PubMed ID: 27557509
    [Abstract] [Full Text] [Related]

  • 13. Screening and Activity Evaluation of Novel BCR-ABL/T315I Tyrosine Kinase Inhibitors.
    Su J, Fu C, Wang S, Chen X, Wang R, Shi H, Li J, Wang X.
    Curr Med Chem; 2024 May 02; 31(20):2872-2894. PubMed ID: 37211852
    [Abstract] [Full Text] [Related]

  • 14. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
    You L, Liu H, Huang J, Xie W, Wei J, Ye X, Qian W.
    Oncotarget; 2017 Jan 31; 8(5):7777-7790. PubMed ID: 27999193
    [Abstract] [Full Text] [Related]

  • 15. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.
    Kim SJ, Jung KH, Yan HH, Son MK, Fang Z, Ryu YL, Lee H, Lim JH, Suh JK, Kim J, Lee S, Hong S, Hong SS.
    Oncotarget; 2015 Jan 30; 6(3):1507-18. PubMed ID: 25483100
    [Abstract] [Full Text] [Related]

  • 16. Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation.
    Lan X, Zhao C, Chen X, Zhang P, Zang D, Wu J, Chen J, Long H, Yang L, Huang H, Wang X, Shi X, Liu J.
    Cell Death Dis; 2017 Jul 06; 8(7):e2913. PubMed ID: 28682311
    [Abstract] [Full Text] [Related]

  • 17. JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia.
    Aranda-Tavío H, Recio C, Martín-Acosta P, Guerra-Rodríguez M, Brito-Casillas Y, Blanco R, Junco V, León J, Montero JC, Gandullo-Sánchez L, McNaughton-Smith G, Zapata JM, Pandiella A, Amesty A, Estévez-Braun A, Fernández-Pérez L, Guerra B.
    Biomed Pharmacother; 2021 Dec 06; 144():112330. PubMed ID: 34673425
    [Abstract] [Full Text] [Related]

  • 18. Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia.
    Liu X, Wang B, Chen C, Jiang Z, Hu C, Wu H, Zhang Y, Liu X, Wang W, Wang J, Hu Z, Wang A, Huang T, Liu Q, Wang W, Wang L, Wang W, Ren T, Li L, Xia R, Ge J, Liu Q, Liu J.
    Eur J Med Chem; 2018 Dec 05; 160():61-81. PubMed ID: 30317026
    [Abstract] [Full Text] [Related]

  • 19. MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.
    Yeh YY, Liou JP, Lee YL, Lin JY, Huang HM.
    Invest New Drugs; 2017 Aug 05; 35(4):427-435. PubMed ID: 28349229
    [Abstract] [Full Text] [Related]

  • 20. Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.
    Wang LX, Wang JD, Chen JJ, Long B, Liu LL, Tu XX, Luo Y, Hu Y, Lin DJ, Lu G, Long ZJ, Liu Q.
    Sci Rep; 2016 Nov 08; 6():35533. PubMed ID: 27824120
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.